Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma

Blood

Volumn 123, Issue 11, 2014, Pages 1681-1690

  Bouska, Alyssa ^a   McKeithan, Timothy W ^a   Deffenbacher, Karen E ^a   Lachel, Cynthia ^a   Wright, George W ^b   Iqbal, Javeed ^a   Smith, Lynette M ^a   Zhang, Weiwei ^a   Kucuk, Can ^a   Rinaldi, Andrea ^c   Bertoni, Francesco ^c,d   Fitzgibbon, Jude ^e   Fu, Kai ^a   Weisenburger, Dennis D ^f   Greiner, Timothy C ^a   Dave, Bhavana J ^a   Gascoyne, Randy D ^g   Rosenwald, Andreas ^h   Ott, German ⁱ   Campo, Elias ^j   Rimsza, Lisa M ^k   Delabie, Jan ^l   Jaffe, Elaine S ^b   Braziel, Rita M ^m   Connors, Joseph M ^g   Staudt, Louis M ^b   Chan, Wing Chung ^a   more..

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^d ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g BRITISH COLUMBIA CANCER AGENCY   (Canada)

^h UNIVERSITY OF WÜRZBURG   (Germany)

ⁱ DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^j HOSPITAL CLÍNIC   (Spain)

^k UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^l UNIVERSITY OF TORONTO   (Canada)

^m OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR;

ARTICLE; B LYMPHOCYTE; CANCER PATIENT; CHROMOSOME 11; CHROMOSOME 12; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME 18; CHROMOSOME 2; CHROMOSOME 21; CHROMOSOME 5; CHROMOSOME 6P; CHROMOSOME 6Q; CHROMOSOME 7; CHROMOSOME 8; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME XP; CONTROLLED STUDY; FOLLICULAR LYMPHOMA; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC DISORDER; HUMAN; HUMAN TISSUE; IMMUNOSURVEILLANCE; LARGE CELL LYMPHOMA; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT DISEASE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSFORMED FOLLICULAR LYMPHOMA; X CHROMOSOME;

CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; DNA COPY NUMBER VARIATIONS; DNA, NEOPLASM; GENE EXPRESSION PROFILING; GENOME, HUMAN; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SURVIVAL RATE; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84897510639     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-500595     Document Type: Article

References (56)

1. Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. J Clin Invest. 2012;122(10):3424-3431.
2. Cheung KJ, Delaney A, Ben-Neriah S, et al. High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copy-neutral loss of heterozygosity and copy number alterations that target single genes. Genes Chromosomes Cancer. 2010;49(8):669-681.
3. Cheung KJ, Shah SP, Steidl C, et al. Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. Blood. 2009;113(1):137-148.
4. Höglund M, Sehn L, Connors JM, et al. Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. Genes Chromosomes Cancer. 2004;39(3):195-204. (Pubitemid 38209580)
5. Horsman DE, Connors JM, Pantzar T, Gascoyne RD. Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). Genes Chromosomes Cancer. 2001;30(4):375-382. (Pubitemid 32216328)
6. Ross CW, Ouillette PD, Saddler CM, Shedden KA, Malek SN. Comprehensive analysis of copy number and allele status identifies multiple chromosome defects underlying follicular lymphoma pathogenesis. Clin Cancer Res. 2007;13(16):4777-4785. (Pubitemid 47294784)
7. d'Amore F, Chan E, Iqbal J, et al. Clonal evolution in t(14;18)-positive follicular lymphoma, evidence for multiple common pathways, and frequent parallel clonal evolution. Clin Cancer Res. 2008;14(22):7180-7187.
8. Batstone PJ, Goodlad JR. Efficacy of screening the intermediate cluster region of the bcl2 gene in follicular lymphomas by PCR. J Clin Pathol. 2005;58(1):81-82. (Pubitemid 40070502)
9. Huang JZ, Sanger WG, Greiner TC, et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood. 2002;99(7):2285-2290. (Pubitemid 34525409)
10. Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA. 2008;105(36):13520-13525.
11. Venkatraman ES, Olshen AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics. 2007;23(6):657-663. (Pubitemid 46554715)
12. Yamamoto G, Nannya Y, Kato M, et al. Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet. 2007;81(1):114-126. (Pubitemid 47001161)
13. Pinheiro I, Margueron R, Shukeir N, et al. Prdm3 and Prdm16 are H3K9me1 methyltransferases required for mammalian heterochromatin integrity. Cell. 2012;150(5):948-960.
14. Cheung KJ, Johnson NA, Affleck JG, et al. Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. Cancer Res. 2010;70(22):9166-9174.
15. Launay E, Pangault C, Bertrand P, et al. High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis. Leukemia. 2012;26(3):559-562.
16. O'Shea D, O'Riain C, Gupta M, et al. Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. Blood. 2009;113(10):2298-2301.
17. Fitzgibbon J, Iqbal S, Davies A, et al. Genome-wide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphoma. Leukemia. 2007;21(7):1514-1520. (Pubitemid 46965294)
18. Höglund M, Gisselsson D, Säll T, Mitelman F. Coping with complexity. Multivariate analysis of tumor karyotypes. Cancer Genet Cytogenet. 2002;135(2):103-109. (Pubitemid 34786761)
19. Li Y, Vecchiarelli-Federico LM, Li YJ, et al. The miR-17-92 cluster expands multipotent hematopoietic progenitors whereas imbalanced expression of its individual oncogenic miRNAs promotes leukemia in mice. Blood. 2012;119(19):4486-4498.
20. Liu X, Wang C, Chen Z, et al. MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. Biochem J. 2011;440(1):23-31.
21. Leich E, Zamo A, Horn H, et al. MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype. Blood. 2011;118(20):5550-5558.
22. Scandurra M, Mian M, Greiner TC, et al. Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. Br J Haematol. 2010;151(3):221-231.
23. Kepler TB, Perelson AS. Somatic hypermutation in B cells: an optimal control treatment. J Theor Biol. 1993;164(1):37-64.
24. Shahaf G, Barak M, Zuckerman NS, Swerdlin N, Gorfine M, Mehr R. Antigen-driven selection in germinal centers as reflected by the shape characteristics of immunoglobulin gene lineage trees: a large-scale simulation study. J Theor Biol. 2008;255(2):210-222.
25. Victora GD, Schwickert TA, Fooksman DR, et al. Germinal center dynamics revealed by multiphoton microscopy with a photoactivatable fluorescent reporter. Cell. 2010;143(4):592-605.
26. Dominguez-Sola D, Victora GD, Ying CY, et al. The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry. Nat Immunol. 2012;13(11):1083-1091.
27. Cattoretti G. MYC expression and distribution in normal mature lymphoid cells. J Pathol. 2013;229(3):430-440.
28. Thompson RC, Herscovitch M, Zhao I, Ford TJ, Gilmore TD. NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway. J Biol Chem. 2011;286(3):1675-1682.
29. Polo JM, Ci W, Licht JD, Melnick A. Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B cells. Blood. 2008;112(3):644-651.
30. Basso K, Schneider C, Shen Q, et al. BCL6 positively regulates AID and germinal center gene expression via repression of miR-155. J Exp Med. 2012;209(13):2455-2465.
31. Guan B, Wang TL, Shih IM. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011;71(21):6718-6727.
32. Schwickart M, Huang X, Lill JR, et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature. 2010;463(7277):103-107.
33. Huynh KD, Fischle W, Verdin E, Bardwell VJ. BCoR, a novel corepressor involved in BCL-6 repression. Genes Dev. 2000;14(14):1810-1823. (Pubitemid 30602999)
34. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365(26): 2497-2506.
35. Botlagunta M, Vesuna F, Mironchik Y, et al. Oncogenic role of DDX3 in breast cancer biogenesis. Oncogene. 2008;27(28):3912-3922. (Pubitemid 351913638)
36. Jankowska AM, Makishima H, Tiu RV, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood. 2011;118(14):3932-3941.
37. Paolicchi E, Crea F, Farrar WL, Green JE, Danesi R. Histone lysine demethylases in breast cancer. Crit Rev Oncol Hematol. 2013;86(2):97-103.
38. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99(24):15524-15529. (Pubitemid 35403967)
39. Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490(7418):116-120.
40. Monti S, Chapuy B, Takeyama K, et al. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell. 2012;22(3):359-372.
41. Cheung KJ, Horsman DE, Gascoyne RD. The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target. Br J Haematol. 2009;146(3):257-269.
42. Chaturvedi MM, Sung B, Yadav VR, Kannappan R, Aggarwal BB. NF-κB addiction and its role in cancer: 'one size does not fit all'. Oncogene. 2011;30(14):1615-1630.
43. Liu W, Quinto I, Chen X, et al. Direct inhibition of Bruton's tyrosine kinase by IBtk, a Btk-binding protein. Nat Immunol. 2001;2(10):939-946. (Pubitemid 32976166)
44. Gupta N, Delrow J, Drawid A, Sengupta AM, Fan G, Gélinas C. Repression of B-cell linker (BLNK) and B-cell adaptor for phosphoinositide 3-kinase (BCAP) is important for lymphocyte transformation by rel proteins. Cancer Res. 2008;68(3):808-814. (Pubitemid 351206758)
45. Hu WH, Pendergast JS, Mo XM, et al. NIBP, a novel NIK and IKK(β)-binding protein that enhances NF-(κ)B activation. J Biol Chem. 2005;280(32):29233-29241. (Pubitemid 41161376)
46. Chen F. Arresting NF-kappaB by β-arrestin2. Cell Death Differ. 2004;11(11):1155-1156.
47. Jeong W, Chang TS, Boja ES, Fales HM, Rhee SG. Roles of TRP14, a thioredoxin-related protein in tumor necrosis factor-alpha signaling pathways. J Biol Chem. 2004;279(5):3151-3159. (Pubitemid 38140547)
48. Clark JM, Aleksiyadis K, Martin A, et al. Inhibitor of kappa B epsilon (IκBε) is a non-redundant regulator of c-Rel-dependent gene expression in murine T and B cells. PLoS ONE. 2011;6(9):e24504.
49. Gerondakis S, Grumont R, Rourke I, Grossmann M. The regulation and roles of Rel/NF-κ B transcription factors during lymphocyte activation. Curr Opin Immunol. 1998;10(3):353-359. (Pubitemid 28286963)
50. Mansson R, Welinder E, Åhsberg J, et al. Positive intergenic feedback circuitry, involving EBF1 and FOXO1, orchestrates B-cell fate. Proc Natl Acad Sci USA. 2012;109(51):21028-21033.
51. Seifert M, Sellmann L, Bloehdorn J, et al. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med. 2012;209(12):2183- 2198.
52. Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43(9):830-837.
53. M'Hidi H, Thibult ML, Chetaille B, et al. High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Am J Clin Pathol. 2009;132(4):589-596.
54. Kashiwakuma D, Suto A, Hiramatsu Y, et al. B and T lymphocyte attenuator suppresses IL-21 production from follicular Th cells and subsequent humoral immune responses. J Immunol. 2010;185(5):2730-2736.
55. Bertrand P, Maingonnat C, Penther D, et al. The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B-cell lymphoma. Genes Chromosomes Cancer. 2013;52(8):764-774.
56. Challa-Malladi M, Lieu YK, Califano O, et al. Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell. 2011;20(6):728-740.